Kyverna Therapeutics
KYTXNASDAQEngineered CD19-targeted chimeric antigen receptor (CAR) T-cell therapies designed to reset the immune system by depleting pathogenic B cells in autoimmune diseases.
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-09-09 · where each field comes from
Key figures from SEC filings
KYTX filings on EDGAR →Cash & investments
$199M
at June 30, 2026 (10-Q)
Quarterly operating burn
$41.0M
average per quarter, Jan–Jun 2026
Cash runway
~15 months
$199M ÷ $41.0M per quarter
Shares outstanding
61.8M
cover page of the latest filing
Read from KYTX's XBRL financial data; latest filing August 11, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Pre-revenue.
Upcoming catalysts
No upcoming catalyst for Kyverna Therapeutics has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| KYV-101 | Systemic Sclerosis | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Lupus Nephritis | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Lupus Nephritis (Refractory) | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Progressive Multiple Sclerosis | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Generalized Myasthenia Gravis | Phase 2 | Not disclosed | ▼ |
| KYV-101 | Stiff Person Syndrome | Phase 2 | Not disclosed | ▼ |
| KYV-101 | Rheumatoid Arthritis | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Multiple Sclerosis (Non-relapsing and Progressive) | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Autoimmune Diseases (Multiple) | Phase 1 | Not disclosed | ▼ |
| KYV-101 | Long-term Follow-up | NDA/BLA Filed | Ongoing | ▼ |
What does Kyverna Therapeutics do?
Kyverna Therapeutics is a biotech company that is trying to use a powerful cancer treatment to fight autoimmune diseases. Normally, our immune system protects us, but in autoimmune diseases it mistakenly attacks our own body. Kyverna takes a patient's own immune cells (T cells), engineers them to find and destroy a type of B cell that is causing the trouble, and then infuses them back. This is like a 'reset' for the immune system. The company is testing this approach in diseases like lupus, multiple sclerosis, and rheumatoid arthritis. For investors, the potential is huge because these are chronic diseases affecting millions, and a one-time treatment could be curative. However, this is very early-stage science. Many trials have been stopped early, which is a red flag. The company is also spending a lot of money without any revenue. The key question is whether the treatment works safely and lasts. If it does, Kyverna could be a game-changer, but if not, the stock could be worthless. Investors should watch for data from ongoing trials and any news about manufacturing or safety.
What to watch
Monitor announcements of data from the completed Stiff Person Syndrome trial and any updates on the terminated lupus trials.
Track patient enrollment and any changes to the ongoing phase 2 myasthenia gravis trial.
Watch for updates on manufacturing scale-up and cost reduction initiatives.
Follow presentations at major conferences like ASGCT or ISCT for updated efficacy and safety data.
Keep an eye on cash burn and any financing activities that could dilute shareholders.
Investment thesis
Extreme RiskBull case
Kyverna is pioneering CAR T therapy for autoimmune diseases, a potentially curative approach for millions of patients. Unlike oncology, autoimmune diseases are chronic and often affect younger patients, creating a large market. The company's lead asset, KYV-101, has shown promising early data in lupus nephritis and other indications, with a manageable safety profile. If the platform works across multiple diseases, Kyverna could become a leader in a new class of medicines. With a strong cash position and multiple ongoing trials, the company has multiple shots on goal. The recent completion of a phase 2 trial in Stiff Person Syndrome and ongoing phase 2 in myasthenia gravis could provide near-term catalysts. If durability of response is confirmed, Kyverna could command premium pricing and significant market share.
Bear case
Kyverna faces significant challenges. Manufacturing CAR T cells is complex and expensive, leading to high costs and potential pricing hurdles. The durability of response is unproven; patients may relapse after initial improvement. Several trials have been terminated, raising concerns about execution and data quality. The company is pre-revenue and burning cash rapidly, requiring future dilution. Competition is intense, with larger players like Novartis and Cabaletta also developing CAR T therapies for autoimmune diseases. Regulatory hurdles are high, and safety concerns like cytokine release syndrome and neurotoxicity remain. If early data fail to replicate or durability is poor, the stock could plummet. Additionally, the company's focus on rare autoimmune diseases may limit market size compared to oncology.
Risk factors
Multiple terminated trials indicate potential issues with trial design, recruitment, or safety that could undermine the entire pipeline.
Manufacturing complexity and high cost of goods could limit profitability and market access.
Durability of response is unknown; patients may relapse, reducing the value proposition.
Competition from larger companies with more resources could outpace Kyverna.
Regulatory requirements for cell therapies are stringent; any safety signal could halt development.
Cash runway is limited; additional financing will likely dilute shareholders.
Comparable companies
Sponsored
Get premium KYTX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you